Literature DB >> 12389067

The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH.

Ola Junghard1, Mohammed Hassan-Alin, Göran Hasselgren.   

Abstract

OBJECTIVE: The aim of this study was to create a useful model of the effect of the area under the plasma concentration vs time curve (AUC) and the maximum plasma concentration (C(max)) of esomeprazole on intragastric pH, measured as the percentage of total time with intragastric pH above 4 (%pH>4) during a 24-h period.
METHODS: The evaluation is based on esomeprazole data from two crossover studies. In the first study ( n=36), intragastric pH and plasma concentrations were measured on day 5 of repeated once-daily 20-mg and 40-mg doses of esomeprazole during fasting conditions. In the second study ( n=24), measurements were made on days 1 and 5 of repeated once-daily dosing with 40 mg of esomeprazole under fasting and fed conditions. A model was applied in which the logistic function of %pH>4 was assumed to be linearly dependent on log-transformed AUC and C(max). The effects of repeated dosing and of fed relative to fasting conditions were included in the model, and the interindividual variation in %pH>4 was accounted for.
RESULTS: The effect of the pharmacokinetic variables AUC and C(max) of esomeprazole on %pH>4 can be adequately described by a model using a logistic function for %pH>4 and a normally distributed error. In this model, log-transformed AUC and C(max) were both statistically significant. The model showed that for a fixed AUC, a decrease in C(max) gives an increase in %pH>4. A decrease in AUC, keeping C(max) fixed, gives a decrease in %pH>4, but a simultaneous decrease in C(max) and AUC will result in a less pronounced decrease in %pH>4. The model may be used for predicting differences in %pH>4 between two formulations, based on assessments of AUC and C(max). Repeated dosing gave an increased %pH>4, where approximately half of the increase stemmed from increased AUC and C(max), and the rest could be attributable to the persistent blockade of the proton pumps. Food intake reduced AUC and C(max) but had no obvious effect on %pH>4, which is explained by a prolonged time period with quantifiable plasma concentrations.
CONCLUSION: The effect of the pharmacokinetic variables AUC and C(max) of esomeprazole on %pH>4 can be adequately described by a model using a logistic function for %pH>4 and a normally distributed error.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12389067     DOI: 10.1007/s00228-002-0502-1

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  19 in total

1.  Identification of the time-point which gives a plasma rabeprazole concentration that adequately reflects the area under the concentration-time curve.

Authors:  Takenori Niioka; Tsukasa Uno; Norio Yasui-Furukori; Mikiko Shimizu; Kazunobu Sugawara; Tomonori Tateishi
Journal:  Eur J Clin Pharmacol       Date:  2006-08-17       Impact factor: 2.953

2.  Impact of CYP2C19 polymorphisms on the clinical action of proton pump inhibitors (PPIs).

Authors:  Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2008-10-29       Impact factor: 2.953

3.  Dose-response relationships of rabeprazole 5, 10, 20, and 40 mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypes.

Authors:  Seiichi Hayato; Setsuo Hasegawa; Seiichiro Hojo; Hiroki Okawa; Hiroaki Abe; Nobuyuki Sugisaki; Masahiro Munesue; Yukio Horai; Akihiro Ohnishi
Journal:  Eur J Clin Pharmacol       Date:  2011-11-23       Impact factor: 2.953

Review 4.  Single-isomer drugs: true therapeutic advances.

Authors:  Tommy Andersson
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 5.  Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults.

Authors:  Kate McKeage; Stephanie K A Blick; Jamie D Croxtall; Katherine A Lyseng-Williamson; Gillian M Keating
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 6.  Stereoselective disposition of proton pump inhibitors.

Authors:  Tommy Andersson; Lars Weidolf
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

7.  Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole.

Authors:  Mark B Sostek; Yusong Chen; Tommy Andersson
Journal:  Br J Clin Pharmacol       Date:  2007-04-10       Impact factor: 4.335

8.  Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg.

Authors:  Michael Kukulka; Corey Eisenberg; Sai Nudurupati
Journal:  Clin Exp Gastroenterol       Date:  2011-09-14

Review 9.  The role of the pharmacist in the selection and use of over-the-counter proton-pump inhibitors.

Authors:  Helen F Boardman; Gordon Heeley
Journal:  Int J Clin Pharm       Date:  2015-06-23

10.  Pharmacokinetics and pharmacodynamics of the proton pump inhibitors.

Authors:  Jai Moo Shin; Nayoung Kim
Journal:  J Neurogastroenterol Motil       Date:  2013-01-08       Impact factor: 4.924

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.